Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

Rhea-AI Summary

Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has announced its upcoming fourth quarter and full year 2024 financial results conference call. The event is scheduled for Monday, March 3, 2025, at 8:00 a.m. Eastern Time.

The company will present business updates and financial performance for the period ending December 31, 2024. Interested parties can join via phone by dialing 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast will be available on the Investors & Media section of www.mersana.com, with a replay accessible for approximately 90 days following the presentation.

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

FAQ

When will Mersana Therapeutics (MRSN) report Q4 and full-year 2024 earnings?

Mersana Therapeutics will report its Q4 and full-year 2024 earnings on Monday, March 3, 2025, at 8:00 a.m. Eastern Time.

How can investors access Mersana's (MRSN) Q4 2024 earnings call?

Investors can access the call by dialing 833-255-2826 (domestic) or 412-317-0689 (international), or view the webcast on Mersana's website at www.mersana.com.

How long will Mersana's (MRSN) Q4 2024 earnings webcast be available for replay?

The webcast replay will be available on Mersana's website for approximately 90 days following the conference call.

What is Mersana Therapeutics' (MRSN) primary focus in drug development?

Mersana Therapeutics focuses on discovering and developing antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need.